Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.

Abstract:

:Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events. The costs associated with varenicline are offset by direct savings associated with the reduction in smoking-related diseases. Indeed, despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking. For example, in modelled cost-effectiveness analyses conducted from a healthcare payer perspective, 12 weeks' treatment with varenicline consistently dominated bupropion sustained release and nicotine replacement therapy, and was dominant over, or considered cost effective relative to, unaided cessation, brief counselling or nortriptyline, with regard to the incremental costs per quality-adjusted life-year or life-year gained.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Keating GM,Lyseng-Williamson KA

doi

10.2165/11204710-000000000-00000

subject

Has Abstract

pub_date

2010-09-01 00:00:00

pages

797-800

issue

9

eissn

1172-7047

issn

1179-1934

pii

6

journal_volume

24

pub_type

杂志文章,评审
  • Role of atypical antipsychotics in the treatment of generalized anxiety disorder.

    abstract::Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-014-0162-6

    authors: Hershenberg R,Gros DF,Brawman-Mintzer O

    更新日期:2014-06-01 00:00:00

  • Overview of Current Drug Delivery Methods Across the Blood-Brain Barrier for the Treatment of Primary Brain Tumors.

    abstract::Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00766-w

    authors: Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

    更新日期:2020-11-01 00:00:00

  • Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

    abstract::Hashimoto's encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200721100-00002

    authors: Mocellin R,Walterfang M,Velakoulis D

    更新日期:2007-01-01 00:00:00

  • Sodium Channel Blockers in the Treatment of Epilepsy.

    abstract::Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-017-0441-0

    authors: Brodie MJ

    更新日期:2017-07-01 00:00:00

  • Pharmacotherapy for Friedreich ataxia.

    abstract::Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923030-00003

    authors: Tsou AY,Friedman LS,Wilson RB,Lynch DR

    更新日期:2009-01-01 00:00:00

  • Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.

    abstract::The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by mutations in at least 13 different genes and primarily affect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epi...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00620-8

    authors: Kohlschütter A,Schulz A,Bartsch U,Storch S

    更新日期:2019-04-01 00:00:00

  • Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.

    abstract::Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0299-y

    authors: Chan A,de Seze J,Comabella M

    更新日期:2016-01-01 00:00:00

  • Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.

    abstract::The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00756-y

    authors: Zheng C,Kar I,Chen CK,Sau C,Woodson S,Serra A,Abboud H

    更新日期:2020-09-01 00:00:00

  • Antipsychotic polypharmacy in schizophrenia: benefits and risks.

    abstract::Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient. Surveys of prescribing in psychiatric services internationally have identified the relatively frequent and consistent use of combined antipsychotics, usually for people with established schizophrenia...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587810-000000000-00000

    authors: Barnes TR,Paton C

    更新日期:2011-05-01 00:00:00

  • Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

    abstract::Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00702-y

    authors: Elsayed NA,Yamamoto KM,Froehlich TE

    更新日期:2020-04-01 00:00:00

  • A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

    abstract:INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0359-y

    authors: Chiappini S,Schifano F

    更新日期:2016-07-01 00:00:00

  • Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.

    abstract:BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-013-0102-x

    authors: Sikirica V,Findling RL,Signorovitch J,Erder MH,Dammerman R,Hodgkins P,Lu M,Xie J,Wu EQ

    更新日期:2013-11-01 00:00:00

  • Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

    abstract::Cognitive dysfunction is a major cause of disability in patients with multiple sclerosis (MS). The prevalence of cognitive dysfunction is estimated at 45 to 65%. Natural history studies suggest that once cognitive dysfunction develops in a patient with MS, it is not likely to remit. Unlike physical disability in MS, c...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216070-00002

    authors: Bagert B,Camplair P,Bourdette D

    更新日期:2002-01-01 00:00:00

  • Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

    abstract::Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other t...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418130-00003

    authors: Desai AK,Grossberg GT,Sheth DN

    更新日期:2004-01-01 00:00:00

  • Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.

    abstract:INTRODUCTION:Both levetiracetam (LEV) and brivaracetam (BRV) eliminate the electroencephalogram photoparoxysmal response (PPR) in the human phase IIa photosensitivity model of epilepsy. The physiochemical properties of BRV differ from those of LEV, having higher potency and lipophilicity plus 10- to 15-fold greater aff...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00761-1

    authors: Reed RC,Rosenfeld WE,Lippmann SM,Eijkemans RMJC,Kasteleijn-Nolst Trenité DGA

    更新日期:2020-10-01 00:00:00

  • Biological markers of age-related memory deficits: treatment of senescent physiology.

    abstract::In humans, age-related memory impairments begin in mid-life and cognitive weakening continues with advancing age. An important aspect of defining memory decline is the distinction between dementia as a result of neurological diseases, such as Alzheimer's disease, and memory loss not specifically associated with diseas...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620020-00006

    authors: Foster TC

    更新日期:2006-01-01 00:00:00

  • Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study.

    abstract:BACKGROUND:Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling ol...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-019-00633-3

    authors: Agustini B,Mohebbi M,Woods RL,McNeil JJ,Nelson MR,Shah RC,Murray AM,Ernst ME,Reid CM,Tonkin A,Lockery JE,Berk M,ASPREE Investigator Group.

    更新日期:2019-07-01 00:00:00

  • Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

    abstract::Schizophrenia is a long-term psychiatric disorder that impacts important mental functions and requires indefinite treatment, as well as psychosocial and economic support. The introduction of chlorpromazine, the first antipsychotic, and the subsequent development of a long list of similar dopamine-blocking antipsychoti...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-018-0588-3

    authors: Awad AG

    更新日期:2019-01-01 00:00:00

  • Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.

    abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00727-3

    authors: Henchcliffe C,Sarva H

    更新日期:2020-06-01 00:00:00

  • Clinical issues in use of atypical antipsychotics for depressed patients.

    abstract::Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-012-0032-z

    authors: Pae CU,Patkar AA

    更新日期:2013-05-01 00:00:00

  • Guide to anaesthetic selection for electroconvulsive therapy.

    abstract::Electroconvulsive therapy (ECT) is used in the treatment of severe psychiatric disorders. It involves the induction of a seizure for therapeutic purposes by the administration of a variable-frequency electrical stimulus via electrodes applied to the scalp. The original application of ECT in non-anaesthetised patients ...

    journal_title:CNS drugs

    pub_type: 指南,杂志文章,实务指引,评审

    doi:10.2165/00023210-200519090-00002

    authors: Wagner KJ,Möllenberg O,Rentrop M,Werner C,Kochs EF

    更新日期:2005-01-01 00:00:00

  • Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study.

    abstract:PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0229-z

    authors: Verrotti A,Parisi P,Agostinelli S,Loiacono G,Marra F,Coppola G,Pisani LR,Gorgone G,Striano P,Pisani F,Belcastro V

    更新日期:2015-02-01 00:00:00

  • Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

    abstract::This review focuses on current information about luteal phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a luteal phase administration regimen reduces the exp...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418070-00004

    authors: Freeman EW

    更新日期:2004-01-01 00:00:00

  • Correction to: Propofol: A Review of its Role in Pediatric Anesthesia and Sedation.

    abstract::The original article can be found online. ...

    journal_title:CNS drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40263-018-0561-1

    authors: Chidambaran V,Costandi A,D'Mello A

    更新日期:2018-09-01 00:00:00

  • Seizures in HIV-seropositive individuals: epidemiology and treatment.

    abstract::Seizures are a relatively common occurrence in patients with HIV infection. They may be a result of HIV infection of the CNS or a manifestation of an opportunistic infection. Because seizures are likely to recur in patients infected with HIV and because they are a poor prognostic indicator, it is generally recommended...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200216020-00002

    authors: Romanelli F,Ryan M

    更新日期:2002-01-01 00:00:00

  • Atypical depression: a comprehensive review.

    abstract::Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11310990-000000000-00000

    authors: Pae CU,Tharwani H,Marks DM,Masand PS,Patkar AA

    更新日期:2009-12-01 00:00:00

  • Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.

    abstract:BACKGROUND:Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the sodium channel current, and acts as a positive allosteric modulator of GABAA rece...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00759-9

    authors: Lattanzi S,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M,Brigo F

    更新日期:2020-11-01 00:00:00

  • Lower IQ is associated with decreased clinical response to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.

    abstract:OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/11590450-000000000-00000

    authors: Mazzone L,Reale L,Mannino V,Cocuzza M,Vitiello B

    更新日期:2011-06-01 00:00:00

  • Ziprasidone.

    abstract::▴ Ziprasidone is a novel antipsychotic drug. It has high affinity for serotonin 5-HT(2) and dopamine D(2) receptors in vitro, with an 11-fold higher affinity for 5-HT(2) than for D(2) receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (EPS)].▴ The effects of zipr...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199708020-00006

    authors: Davis R,Markham A

    更新日期:1997-08-01 00:00:00

  • Bipolar depression: management options.

    abstract::Bipolar depression is the predominant abnormal mood state in bipolar disorder. However, despite the key pertinence of this phase of the condition, the focus of research and indeed of clinical interest in the management of bipolar disorder has been mainly on mania. Bipolar depression has been largely neglected, and ear...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317010-00002

    authors: Malhi GS,Mitchell PB,Salim S

    更新日期:2003-01-01 00:00:00